{
    "clinical_study": {
        "@rank": "100695", 
        "acronym": "PERFLEX", 
        "arm_group": {
            "arm_group_label": "Paliperidone ER", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate efficacy, safety and tolerability of flexible,\n      once-daily doses of paliperidone extended-release (ER) in patients with schizophrenia from\n      Argentina and Colombia that previously failed treatment with other antipsychotic agents."
        }, 
        "brief_title": "Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                        "title": "Paliperidone Extended-release (ER)"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "95"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "12.28", 
                                            "@value": "35.86"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "41"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "54"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "37"
                                            }
                                        }, 
                                        "sub_title": "Argentina"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "58"
                                            }
                                        }, 
                                        "sub_title": "Colombia"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "70"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "22.16", 
                                                        "@value": "83.99"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 70)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.82", 
                                                        "@value": "53.70"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 70)"
                                            }
                                        ]
                                    }, 
                                    "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "70"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "7.30", 
                                                        "@value": "18.53"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 70)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.95", 
                                                        "@value": "11.16"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 70)"
                                            }
                                        ]
                                    }, 
                                    "description": "The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "70"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "6.42", 
                                                        "@value": "23.69"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 70)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "5.24", 
                                                        "@value": "14.64"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 70)"
                                            }
                                        ]
                                    }, 
                                    "description": "The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "70"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.39", 
                                                        "@value": "41.77"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 70)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "10.34", 
                                                        "@value": "27.90"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 70)"
                                            }
                                        ]
                                    }, 
                                    "description": "The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill patients\". Higher scores indicate worsening.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                    "title": "Patients at Baseline: Paliperidone Extended-release (ER)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                    "title": "Patients at Week 26: Paliperidone Extended-release (ER)"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "95"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "83"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "2"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "9"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Normal, not at all ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "3"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "21"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Borderline mentally ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "14"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "26"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Mildly ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "39"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "20"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Moderately ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "26"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "5"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Markedly ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "10"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Severely ill"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Among the most extremely ill"
                                            }
                                        ]
                                    }, 
                                    "description": "The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill patients\". Higher scores indicate worsening.", 
                                    "param": "Number", 
                                    "title": "Clinical Global Impression-Severity (CGIS)", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Clinical Global Impression-Severity (CGIS)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "This PSP assesses the degree of a patient\u2019s dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =< 30, functioning so poorly as to require intensive supervision.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "95"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "15.27", 
                                                        "@value": "52.06"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 95)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "15.91", 
                                                        "@value": "68.24"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 78)"
                                            }
                                        ]
                                    }, 
                                    "description": "This PSP assesses the degree of a patient\u2019s dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =< 30, functioning so poorly as to require intensive supervision.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Personal and Social Performance (PSP) Scale", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Personal and Social Performance (PSP) Scale", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The SF-36 is designed to examine a person\u2019s perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 \u2013 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "95"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.14", 
                                                        "@value": "56.39"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 95)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "21.56", 
                                                        "@value": "67.02"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 86)"
                                            }
                                        ]
                                    }, 
                                    "description": "The SF-36 is designed to examine a person\u2019s perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 \u2013 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Health Status as Measured by Self-rated Health Status Survey SF-36", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Health Status as Measured by Self-rated Health Status Survey SF-36", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "This self-administered scale rates the quality of sleep. Patients will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "71"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.69", 
                                                        "@value": "6.80"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 71)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.52", 
                                                        "@value": "7.66"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 71)"
                                            }
                                        ]
                                    }, 
                                    "description": "This self-administered scale rates the quality of sleep. Patients will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Sleep Evaluation Scale", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Sleep Evaluation Scale", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "This self-administered scale rates the daytime drowsiness. Patients will indicate on an 11-point scale how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                                "title": "Paliperidone Extended-release (ER)"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "71"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "3.21", 
                                                        "@value": "4.68"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n= 71)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.93", 
                                                        "@value": "2.58"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n= 71)"
                                            }
                                        ]
                                    }, 
                                    "description": "This self-administered scale rates the daytime drowsiness. Patients will indicate on an 11-point scale how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Daytime Drowsiness Evaluation Scale", 
                                    "units": "scores on a scale"
                                }
                            ]
                        }, 
                        "population": "All participants of the intent-to-treat analysis set for efficacy with evaluable data at each measurement time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 26", 
                        "title": "Daytime Drowsiness Evaluation Scale", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                        "title": "Paliperidone Extended-release (ER)"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Death"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "20", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Not specified"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "95", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "64", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "31", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Patients who received paliperidone extended-release (ER) at least once and provide at least 1 post baseline efficacy measurement will be included in the intent-to-treat (ITT) analysis set for efficacy. Patients who received paliperidone ER at least once and provide any post-baseline information will be included in the ITT analysis set for safety."
            }, 
            "point_of_contact": {
                "name_or_title": "GERENTE MEDICO REGIONAL", 
                "organization": "Jan-Cil Mexico", 
                "phone": "52 55 5237 3410"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "The recommended Paliperidone ER dose is 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily.", 
                        "title": "Paliperidone Extended-release (ER)"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "39", 
                                            "@subjects_at_risk": "95"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "22", 
                                                "@subjects_at_risk": "95"
                                            }, 
                                            "sub_title": "Akathisia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "15", 
                                                "@subjects_at_risk": "95"
                                            }, 
                                            "sub_title": "Parkinsonism"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "24", 
                                            "@subjects_at_risk": "95"
                                        }, 
                                        "sub_title": "Insomnia"
                                    }
                                }, 
                                "title": "Psychiatric disorders"
                            }
                        ]
                    }, 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "7", 
                                            "@subjects_at_risk": "95"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "95"
                                        }, 
                                        "sub_title": "Appendicitis"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "95"
                                        }, 
                                        "sub_title": "Clinical deterioration"
                                    }
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "95"
                                            }, 
                                            "sub_title": "Psychotic episode"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "95"
                                            }, 
                                            "sub_title": "Major depressive disorder"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "95"
                                            }, 
                                            "sub_title": "Worsening of the psychiatric condition with aggressive behavior"
                                        }
                                    ]
                                }, 
                                "title": "Psychiatric disorders"
                            }
                        ]
                    }
                }
            }
        }, 
        "completion_date": {
            "#text": "November 2009", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "This is a single arm (one group of patients), open-label (all people know the identity of\n      the intervention) multicenter 6-month study. Throughout the study flexible dosing of\n      paliperidone ER in a range of 3 to 12 mg/day may be used. Flexible dosing will allow\n      investigators to adjust the dosage of each patient based on the individual needs. Patients\n      will receive 3, 6, 9 or 12 mg of paliperidone ER once daily for 6 months. The tablets will\n      be taken orally. Adjustment of the dosage will be done at the investigator's discretion,\n      based on the individual patient's clinical response and tolerability to the study drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient meets the criteria for schizophrenia\n\n          -  Patient is previously non-acute and has been given an adequate dose of an appropriate\n             oral antipsychotic for an adequate period of time prior to enrollment, but previous\n             treatment is considered unsuccessful due to one or more of the following reasons:\n             lack of efficacy, lack of tolerability or safety, lack of compliance and/or other\n             reasons to switch to another antipsychotic medication\n\n          -  Patient is healthy on the basis of a physical examination and vital signs at\n             screening\n\n          -  Women must be postmenopausal for at least 1 year, surgically sterile, abstinent, or,\n             if sexually active, agree to practice an effective method of birth control before\n             entry and throughout the study\n\n        Exclusion Criteria:\n\n          -  Patients on clozapine, any conventional depot neuroleptic or risperidone long-acting\n             injections during the last 3 months\n\n          -  Patients with serious unstable medical condition, including known clinically relevant\n             laboratory abnormalities\n\n          -  Patients with history or current symptoms of tardive dyskinesia and neuroleptic\n             malignant syndrome\n\n          -  Patients judged to be at high risk for adverse events, violence, or self-harm\n\n          -  Patients with known hypersensitivity to paliperidone ER or to risperidone\n\n          -  Patients with a current use or known history (over the past 6 months) of substance\n             dependence"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "firstreceived_results_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724359", 
            "org_study_id": "CR017413", 
            "secondary_id": [
                "R076477SCH3029", 
                "R076477SCH3036"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Paliperidone ER", 
            "description": "The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.", 
            "intervention_name": "Paliperidone ER", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "9-hydroxy-risperidone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Paliperidone extended-release (ER)", 
            "Antipsychotic agents"
        ], 
        "lastchanged_date": "February 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires N/A", 
                        "country": "Argentina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosario", 
                        "country": "Argentina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cali", 
                        "country": "Colombia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medellin", 
                        "country": "Colombia"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Argentina", 
                "Colombia", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia", 
        "overall_official": {
            "affiliation": "Janssen-Cilag, S.A.", 
            "last_name": "Janssen-Cilag S.A. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.", 
            "measure": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                "measure": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).", 
                "measure": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).", 
                "measure": "Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill patients\". Higher scores indicate worsening.", 
                "measure": "Clinical Global Impression-Severity (CGIS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "This PSP assesses the degree of a patient's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =< 30, functioning so poorly as to require intensive supervision.", 
                "measure": "Personal and Social Performance (PSP) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "The SF-36 is designed to examine a person's perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 - 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.", 
                "measure": "Health Status as Measured by Self-rated Health Status Survey SF-36", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "This self-administered scale rates the quality of sleep. Patients will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well).", 
                "measure": "Sleep Evaluation Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }, 
            {
                "description": "This self-administered scale rates the daytime drowsiness. Patients will indicate on an 11-point scale how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).", 
                "measure": "Daytime Drowsiness Evaluation Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }
        ], 
        "source": "Janssen-Cilag, S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen-Cilag, S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}